JP2015536927A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015536927A5 JP2015536927A5 JP2015538467A JP2015538467A JP2015536927A5 JP 2015536927 A5 JP2015536927 A5 JP 2015536927A5 JP 2015538467 A JP2015538467 A JP 2015538467A JP 2015538467 A JP2015538467 A JP 2015538467A JP 2015536927 A5 JP2015536927 A5 JP 2015536927A5
- Authority
- JP
- Japan
- Prior art keywords
- substituted
- branched
- unsubstituted
- unbranched
- moiety
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261719284P | 2012-10-26 | 2012-10-26 | |
| EP12382414.6 | 2012-10-26 | ||
| US61/719,284 | 2012-10-26 | ||
| EP12382414 | 2012-10-26 | ||
| PCT/EP2013/072410 WO2014064257A1 (en) | 2012-10-26 | 2013-10-25 | Compositions and methods for the treatment of parkinson disease by the selective delivery of oligonucleotide molecules to specific neuron types |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015536927A JP2015536927A (ja) | 2015-12-24 |
| JP2015536927A5 true JP2015536927A5 (enExample) | 2016-12-15 |
| JP6386461B2 JP6386461B2 (ja) | 2018-09-05 |
Family
ID=47148690
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015538467A Active JP6386461B2 (ja) | 2012-10-26 | 2013-10-25 | 特定のニューロン種へのオリゴヌクレオチド分子の選択的送達によるパーキンソン病の治療のための組成物および方法 |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US9084825B2 (enExample) |
| EP (1) | EP2911695B1 (enExample) |
| JP (1) | JP6386461B2 (enExample) |
| CN (1) | CN104884094A (enExample) |
| AU (1) | AU2013336581A1 (enExample) |
| CA (1) | CA2890112A1 (enExample) |
| ES (1) | ES2967530T3 (enExample) |
| HK (1) | HK1214179A1 (enExample) |
| MX (1) | MX2015005352A (enExample) |
| WO (1) | WO2014064257A1 (enExample) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK2560687T3 (en) | 2010-04-19 | 2017-09-18 | Nlife Therapeutics S L | Preparations and Methods for Selective Delivery of Oligonucleotide Molecules to Specific Neuron Types |
| AU2011329777B2 (en) | 2010-11-17 | 2016-06-09 | Ionis Pharmaceuticals, Inc. | Modulation of alpha synuclein expression |
| CA2844012C (en) | 2011-08-04 | 2021-03-16 | Yeda Research And Development Co. Ltd. | Micro-rnas and compositions comprising same for the treatment and diagnosis of serotonin-, adrenalin-, noradrenalin-, glutamate-, and corticotropin-releasing hormone- associated medical conditions |
| AU2013336581A1 (en) | 2012-10-26 | 2015-06-11 | Nlife Therapeutics, S.L. | Compositions and methods for the treatment of Parkinson disease by the selective delivery of oligonucleotide molecules to specific neuron types |
| CN106715695B (zh) | 2014-02-05 | 2020-07-31 | 耶达研究及发展有限公司 | 用于治疗和诊断的微rna和包含所述微rna的组合物 |
| WO2016186968A1 (en) | 2015-05-15 | 2016-11-24 | The Arizona Board Of Regents On Behalf Of The University Of Arizona | Compositions and methods for treating motor disorders |
| MA43072A (fr) | 2015-07-22 | 2018-05-30 | Wave Life Sciences Ltd | Compositions d'oligonucléotides et procédés associés |
| US10733023B1 (en) * | 2015-08-06 | 2020-08-04 | D2Iq, Inc. | Oversubscription scheduling |
| US11234995B2 (en) | 2016-01-07 | 2022-02-01 | Osaka University | α-synuclein expression inhibitor |
| MA45328A (fr) | 2016-04-01 | 2019-02-06 | Avidity Biosciences Llc | Compositions acide nucléique-polypeptide et utilisations de celles-ci |
| EP3628737A4 (en) * | 2017-07-05 | 2021-01-20 | Osaka University | ENA-ANTISENSE-OLIGONUCLEOTIDE TO INHIBIT ALPHA-SYNUCLEIN EXPRESSION |
| WO2019009298A1 (ja) * | 2017-07-05 | 2019-01-10 | 国立大学法人大阪大学 | α－シヌクレイン発現抑制剤 |
| KR101890925B1 (ko) | 2017-08-08 | 2018-08-24 | 주식회사 이레산업 | 캠핑용 그릴 세트 |
| SG11202003126VA (en) * | 2017-10-04 | 2020-05-28 | Avidity Biosciences Inc | Nucleic acid-polypeptide compositions and uses thereof |
| WO2019079887A1 (en) * | 2017-10-23 | 2019-05-02 | Carleton University | APTAMERS AS A THERAPEUTIC TO PREVENT AGGREGATION OF PROTEINS IN NEURODEGENERATIVE DISEASE |
| TWI809004B (zh) * | 2017-11-09 | 2023-07-21 | 美商Ionis製藥公司 | 用於降低snca表現之化合物及方法 |
| KR102839166B1 (ko) | 2018-01-12 | 2025-07-28 | 브리스톨-마이어스 스큅 컴퍼니 | 알파-시누클레인을 표적화하는 안티센스 올리고뉴클레오티드 및 그의 용도 |
| JP2021511027A (ja) | 2018-01-12 | 2021-05-06 | ロシュ・イノベーション・センター・コペンハーゲン・アクティーゼルスカブＲｏｃｈｅ Ｉｎｎｏｖａｔｉｏｎ Ｃｅｎｔｅｒ Ｃｏｐｅｎｈａｇｅｎ Ａ／Ｓ | アルファ−シヌクレインアンチセンスオリゴヌクレオチド及びその使用 |
| IL280880B2 (en) | 2018-08-27 | 2025-04-01 | Regeneron Pharma | Using Raman Spectroscopy in Downstream Purification |
| US20220096665A1 (en) * | 2018-11-21 | 2022-03-31 | University Of Georgia Research Foundation, Inc. | Bimodal nanoparticle conjugates for non-invasive central nervous system tissue imaging |
| US20220127605A1 (en) * | 2018-11-30 | 2022-04-28 | Kyowa Kirin Co., Ltd. | Nucleic acid conjugate |
| WO2020210207A2 (en) | 2019-04-11 | 2020-10-15 | Northeastern University | Oligonucleotide-polymer miktoarm conjugates and methods of use |
| KR20220019259A (ko) | 2019-06-06 | 2022-02-16 | 어비디티 바이오사이언시스 인크. | Una 아미다이트 및 이의 용도 |
| WO2021094751A1 (en) * | 2019-11-11 | 2021-05-20 | Oxford University Innovation Limited | Biomarkers for the prediction and identification of parkinson's disease |
| CN115168823B (zh) * | 2022-08-05 | 2025-07-18 | 聊城大学 | 基于组平均的多任务功能性近红外光谱信号的身份识别 |
| WO2024166019A1 (en) * | 2023-02-08 | 2024-08-15 | Biorchestra Co., Ltd. | Sirna targeting alpha-synuclein and uses thereof |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL66831A0 (en) | 1981-10-05 | 1982-12-31 | Kefalas As | Indane derivatives |
| US4902505A (en) | 1986-07-30 | 1990-02-20 | Alkermes | Chimeric peptides for neuropeptide delivery through the blood-brain barrier |
| US4904582A (en) | 1987-06-11 | 1990-02-27 | Synthetic Genetics | Novel amphiphilic nucleic acid conjugates |
| US5176996A (en) | 1988-12-20 | 1993-01-05 | Baylor College Of Medicine | Method for making synthetic oligonucleotides which bind specifically to target sites on duplex DNA molecules, by forming a colinear triplex, the synthetic oligonucleotides and methods of use |
| US5256775A (en) | 1989-06-05 | 1993-10-26 | Gilead Sciences, Inc. | Exonuclease-resistant oligonucleotides |
| US5264564A (en) | 1989-10-24 | 1993-11-23 | Gilead Sciences | Oligonucleotide analogs with novel linkages |
| US6455736B1 (en) | 1994-12-16 | 2002-09-24 | Uop Llc | Process for preparation of pharmaceutically desired sertraline and sertraline analogs |
| ATE373672T1 (de) | 1996-01-16 | 2007-10-15 | Sirna Therapeutics Inc | Synthese von methoxynukleoside und enzymatische nukleisäure moleküle |
| WO2006006948A2 (en) * | 2002-11-14 | 2006-01-19 | Dharmacon, Inc. | METHODS AND COMPOSITIONS FOR SELECTING siRNA OF IMPROVED FUNCTIONALITY |
| EP1635763B1 (en) * | 2003-06-09 | 2012-08-08 | Alnylam Pharmaceuticals Inc. | Method of treating neurodegenerative disease |
| JP2007525211A (ja) * | 2004-01-19 | 2007-09-06 | テクニオン リサーチ アンド ディベロップメント ファウンデーション リミテッド | パーキンソン病の診断検査 |
| WO2007050789A2 (en) * | 2005-10-25 | 2007-05-03 | Nëdken Corporation | Glycosyl-oligonucleotide conjugates and methods |
| GB0605337D0 (en) | 2006-03-17 | 2006-04-26 | Genomica Sau | Treatment of CNS conditions |
| WO2009079399A2 (en) * | 2007-12-14 | 2009-06-25 | Alnylam Pharmaceuticals, Inc. | Method of treating neurodegenerative disease |
| MX2010006925A (es) | 2007-12-20 | 2011-05-02 | Angiochem Inc | Conjugados de polipeptido-acido nucleico y sus usos. |
| US9255266B2 (en) * | 2009-05-06 | 2016-02-09 | Rutgers, The State University Of New Jersey | RNA targeting in alpha-synucleinopathies |
| WO2011087804A2 (en) | 2009-12-21 | 2011-07-21 | Medtronic, Inc. | Peptide-polynucleotide compositions, and methods for transfecting a cell with dna and treatment of neurodegenerative disease |
| DK2560687T3 (en) | 2010-04-19 | 2017-09-18 | Nlife Therapeutics S L | Preparations and Methods for Selective Delivery of Oligonucleotide Molecules to Specific Neuron Types |
| WO2012027713A2 (en) | 2010-08-26 | 2012-03-01 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibition of snca |
| AU2011329777B2 (en) * | 2010-11-17 | 2016-06-09 | Ionis Pharmaceuticals, Inc. | Modulation of alpha synuclein expression |
| US20140315795A1 (en) | 2012-10-26 | 2014-10-23 | Nlife Therapeutics, S.L. | Compositions and Methods for Selective Delivery of Oligonucleotide Molecules to Cell Types |
| AU2013336581A1 (en) | 2012-10-26 | 2015-06-11 | Nlife Therapeutics, S.L. | Compositions and methods for the treatment of Parkinson disease by the selective delivery of oligonucleotide molecules to specific neuron types |
-
2013
- 2013-10-25 AU AU2013336581A patent/AU2013336581A1/en not_active Abandoned
- 2013-10-25 ES ES13783061T patent/ES2967530T3/es active Active
- 2013-10-25 HK HK16102420.8A patent/HK1214179A1/zh unknown
- 2013-10-25 CA CA2890112A patent/CA2890112A1/en not_active Abandoned
- 2013-10-25 MX MX2015005352A patent/MX2015005352A/es unknown
- 2013-10-25 CN CN201380068146.3A patent/CN104884094A/zh active Pending
- 2013-10-25 JP JP2015538467A patent/JP6386461B2/ja active Active
- 2013-10-25 WO PCT/EP2013/072410 patent/WO2014064257A1/en not_active Ceased
- 2013-10-25 EP EP13783061.8A patent/EP2911695B1/en active Active
- 2013-10-28 US US14/065,024 patent/US9084825B2/en active Active - Reinstated
-
2015
- 2015-07-20 US US14/803,811 patent/US10125363B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015536927A5 (enExample) | ||
| US10041074B2 (en) | Euchromatic region targeting methods for modulating gene expression | |
| JP6440170B2 (ja) | キメラ一本鎖アンチセンスポリヌクレオチドおよび二本鎖アンチセンス剤 | |
| BR112020007881A2 (pt) | Oligômeros anti-senso para o tratamento de condições e doenças baseadas no decaimento de rna mediado por nonsense | |
| JP2014527401A5 (enExample) | ||
| JP2012034693A5 (enExample) | ||
| RU2015104762A (ru) | Хиральный контроль | |
| JP7515400B2 (ja) | Ｂ型肝炎ウイルス感染を治療するためのｆｕｂｐ１阻害剤の使用 | |
| JP2015523854A5 (enExample) | ||
| JP2018530530A5 (enExample) | ||
| HRP20160261T1 (hr) | Komplementarni antagonisti i njihova uporaba | |
| HRP20160025T1 (hr) | Sredstva i metode za rješavanje mišiä†nih poremeä†aja | |
| JP2016522674A5 (enExample) | ||
| JP2014509511A5 (enExample) | ||
| JP2013226147A5 (enExample) | ||
| BR112014018427B1 (pt) | Oligonucleotídeos moduladores de rna com características melhoradas para o tratamento da distrofia muscular de duchenne e becker | |
| WO2013192576A3 (en) | Oligonucleotide-based inhibitors comprising locked nucleic acid motif | |
| JP2009514877A5 (enExample) | ||
| JP2018513668A5 (enExample) | ||
| JP2017505623A5 (enExample) | ||
| HRP20191232T1 (hr) | Inhibicija, posredovana rna interferencijom, ekspresije gena virusa hepatitisa b (hbv) korištenjem kratkih interferirajućih nukleinskih kiselina (sina) | |
| JP2017528441A5 (enExample) | ||
| JP2021505129A5 (enExample) | ||
| CA2921457A1 (en) | Heterochromatin forming non-coding rnas | |
| RU2020121752A (ru) | Средство для лечения синдрома ангельмана на основе антисмысловой нуклеиновой кислоты |